Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Merck & Co., Inc.    MRK   US58933Y1055


Delayed Quote. Delayed Nyse - 04/17 04:03:35 pm
56.88 USD   -1.66%
04/15 INTEL : Dow Movers: MCD, INTC
04/14 NEWLINK GENETIC : receives awards for Ebola vaccine work
04/14 MERCK : Phase III Trial of the Merck and NewLink Genetics Investigat..
News SummaryMost relevantAll newsSector news 

Merck Combination Cholesterol Drug Fails to Meet Study Goals; Firm Doesn't Plan to Seek U.S. Approval

12/20/2012 | 09:17am US/Eastern
   By Tess Stynes 

Merck & Co. (>> Merck & Co., Inc.) said its doesn't plan to seek U.S. Food and Drug Administration for a combination cholesterol treatment that aims to reduce the risk of cardiovascular events after the drug failed to meet primary goals in a large long-term study.

Shares were down 2.9% at $42.40 in premarket trading.

The pharmaceutical giant said it isn't recommending that health-care providers start new patients on the treatment--Tredaptive--an extended release combination of niacin and laropiprant. The company also plans to share the study results with health regulators in countries where it also is approved under the Tredaptive or Cordaptive brands.

"While we are disappointed in these results, we thank the investigators who have conducted the study and the patients who have participated in it," said Peter S. Kim, president, Merck Research Laboratories.

The study that compared extended-release niacin and laropiprant plus statin therapy versus statin therapy included 25,673 patients in Britain, Scandinavia and China considered at risk for cardiovascular issues that were followed for a median 3.9 years.

The study found that the combination drug along with statin therapy didn't significantly further reduce the risk of a combination of cardiovascular events such as nonfatal heart attacks, strokes or coronary-related deaths compared with just statin therapy. There also was an increase in nonfatal events in the group receiving Tredaptive.

Further analysis is under way and detailed study results are expected in the first quarter.

Write to Tess Stynes at

Subscribe to WSJ:

Stocks mentioned in the article : Merck & Co., Inc.
React to this article
Latest news on MERCK & CO., INC.
04/16 MERCK : Patent Application Titled "Modified Release Dosage Forms of Skeletal Mus..
04/16 MERCK : Reports Summarize Herpes Zoster Virus Study Results from Merck & Company..
04/16 MERCK : Study Data from Merck & Company Update Knowledge of Hepatitis C Virus [E..
04/15 MERCK : New Clinical Trials and Studies Findings from Merck & Company Outlined (..
04/15 MERCK : Researchers at Merck & Company Target Affective Disorders (Hamilton depr..
04/15 INTEL : Dow Movers: MCD, INTC
04/14 NEWLINK GENETICS : receives awards for Ebola vaccine work
04/14 MERCK : Phase III Trial of the Merck and NewLink Genetics Investigational Ebola ..
04/13DJMerck CEO's 2014 Total Compensation Valued at $25 Million -- Update
04/13DJMerck CEO's 2014 Total Compensation Valued at $25 Million
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes